Navigation Links
As Testosterone Lawsuits Are Filed In The U.S., Canada Warns of Possible Cardiac Risks Associated With Testosterone Medication
Date:7/19/2014

Columbus, OH (PRWEB) July 19, 2014

Wright & Schulte LLC has learned that Health Canada has issued a warning to patients and healthcare professionals of the potential life-threatening heart and blood vessel problems associated with testosterone replacement therapy products. The Canadian regulatory agency said it is working with testosterone drug manufacturers to update their testosterone therapy product labels to reflect the risk of heart attack, stroke, blood clots in the lungs or legs, and increased or irregular heart rate linked with the use of testosterone medication. Meanwhile in the United States, court documents indicate that the number of testosterone lawsuits continue to mount in federal litigation in the U.S. District Court of Illinois against the makers of testosterone replacement therapy products, such as Androderm, AndroGel, Testim and Depo-Testosterone, that all purport men have sustained cardiac events such as strokes and heart attacks due to low testosterone treatment drugs (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
[healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php, July 15, 2014]

Health Canada said in its July 15 safety review that there are 12 testosterone-containing products currently marketed for use as testosterone replacement therapy:

Andriol,
Androderm,
AndroGel, Axiron,
Delatestryl,
Depo-Testosterone,
Testim
and their equivalent generics.

The firm continues to speak with men who have suffered cardiac issues purportedly from low testosterone treatment drugs such as AndroGel and AndroDerm and encourage anyone who believes they have experienced side-effects from testosterone therapy drugs to contact one of their attorneys at 1-800-399-0795 or visit http://www.yourlegalhelp.com for a free legal evaluation. You can also like us on Facebook and follow us on Twitter for all the up to date news.

As of August 31, 2013, Health Canada said it had received 35 reports of cardiovascular problems involving low testosterone treatment products. Of the 35 reports, 11 reports that included heart attack, blood clots in the lungs and irregular heart rate were considered possibly related to testosterone products. Health Canada further stated, some of the cardiovascular problems reported went away when men stopped taking the medication but the problems returned when they started taking the testosterone drug again. Health Canada further said it is working with federal regulatory agencies from other countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, about the safety concerns over testosterone replacement therapy products.

In January, the FDA launched an investigation into the safety of testosterone replacement therapy drugs after reviewing two studies showing potential cardiovascular problems linked with taking low testosterone medication. A study published in the PLOS One Journal on, found that men over 65 and younger men with a pre-existing heart disease who were prescribed testosterone drugs were at a greater risk of having a heart attack within the first 90 days after taking the medication for the first time. The second study, published in the November 2013 Journal of the American Medical Association, found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the medication.

[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014] [plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014] [jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

In June, the FDA ordered manufacturers of all FDA-approved testosterone products to include a general warning about the risk of venous blood clots on their drug labels. Existing testosterone drug labels already have a warning about blood clots in veins as a consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. The FDA, however, said that post-market reports have shown that blood clots are occurring that are unrelated to polycythemia.
[fda.gov/drugs/drugsafety/ucm401746.htm, June 19, 2014]

Testosterone replacement therapy drugs are used to treat hypogonadism (low testosterone) in men who lack or have low testosterone levels due to an underlying medical condition. Among the FDA-approved testosterone products marketed in the U.S. are AndroGel, Androderm, Delatestryl, Depo-Testosterone, Testim and Testope. Testosterone products are manufactured as topical gels, transdermal patches, and as a buccal system applied to upper gum or inner cheek. Some testosterone drugs are injected.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]

According to court records one of the testosterone lawsuits in MDL2545 is an AndroGel lawsuit filed on behalf of a Georgia man who alleges he has had three heart attacks, since January 8, 2013, as a result of taking AndroGel, the low testosterone replacement therapy. The complaint purports that the man was prescribed AndroGel from November 2011 to February 14, 2014 to treat symptoms he attributed to low testosterone based on AndroGel advertisements and that AbbVie Inc., which manufactures AndroGel, wrongly marketed the low testosterone treatment therapy as having few side effects and is a safe method of alleviating symptoms associated with aging. According to the complaint, the Georgia man now has an increased risk of having additional cardiovascular disease, cerebrovascular accidents, and death as a result of his heart attacks allegedly due to taking AndroGel. (Case No: 1:14-cv-01726)

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Read the full story at http://www.prweb.com/releases/2014/07/prweb12030024.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Testosterone Lawsuit News: Bernstein Liebhard LLP Notes Recent Study Finding Dramatic Rise in Canadian Men Taking Hormone Therapy Treatments
2. Number of Testosterone Therapy Lawsuits More than Doubles in Two-Week Period, Baron and Budd Reports
3. FDA Requires Testosterone Medication Manufacturers to Add Expanded Blood Clot Risk to Warning Labels, Baron and Budd Reports
4. Testosterone Treatment Lawsuit: Bernstein Liebhard LLP Notes Health Canada Alert on Possible Association Between Low Testosterone Therapy, Cardiovascular Problems
5. How much testosterone is too much for women after menopause?
6. No credible evidence to support cardiac risk of testosterone therapy
7. Low testosterone levels may indicate worsening of disease for men with prostate cancer
8. The Lancet Diabetes & Endocrinology: Large clinical trials to evaluate risks of testosterone treatment urgently needed
9. Screening instrument to identify testosterone deficiency
10. Male health linked to testosterone exposure in womb, study finds
11. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: